Sanofi's diabetes business shrinks again
Last year's stockpiling due to the covid-19 outbreak has had a severe impact on Sanofi's diabetes business in the first quarter of the year. The French pharmaceutical company has been forced to admit that this business leg has shrunk once again.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
The diabetes business leg of French pharmaceutical company Sanofi has decreased in size in the first three months of the year, according to the Q1 quarterly report which was published early Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sanofi hits bullseye in phase III trial of treatment for RSV
For subscribers
.jpg&w=384&q=75)
